GlassScriptPhysician profile
Daniel R Garlitos
NPI 1386629574
$1,267.16
in general payments reported to CMS, 2019-2025
20 companies · $80.00 in 2025
The $80.00 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $71.88 · 2021: $213 · 2022: $237 · 2023: $334 · 2024: $79.83 · 2025: $80.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.74 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $395.01 | 2019-2023 | |
| Astellas Pharma US INC | $204.12 | 2019-2022 | |
| Seagen INC. | $80.00 | 2025 | |
| Tolmar, INC. | $76.53 | 2023 | |
| Varian Medical Systems, INC. | $66.65 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $51.42 | 2022 | |
| Merck Sharp & Dohme LLC | $44.09 | 2023 | Keytruda |
| Teleflex LLC | $42.45 | 2024 | |
| Tactile Systems Technology INC | $37.80 | 2019-2023 | Flexitouch Plus, Entre Plus |
| Astrazeneca Pharmaceuticals LP | $34.96 | 2019 | |
| Glaxosmithkline, LLC. | $34.54 | 2023 | Shingrix |
| Myriad Genetic Laboratories, INC. | $33.11 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.28 | 2023 | Libtayo |
| Boston Scientific Corporation | $23.69 | 2024 | Rezum Generator |
| Janssen Biotech, INC. | $23.19 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $22.83 | 2023 | Krazati |
| Myovant Sciences INC. | $22.49 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $17.21 | 2022 | |
| Incyte Corporation | $16.10 | 2023 | Jakafi |
| Sumitomo Pharma America, INC. | $13.69 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Garlitos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.